Phase 2 N=7 Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Maximum Tolerated Dose (MTD)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=685 Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
Episodic Migraine
Primary: Percentage of Participants With at Least 1 Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event (TEAEs/TESAEs) — 62.5; 3.4 percentage of…
N/A N=31 Tracking Depression Symptoms With a Health Chatbot
Depression, Postpartum · Depression, Unipolar
Primary: Longitudinal Change in Depression Severity — 16.13; 14.06; 10.47; 10.69 score on a scale — p=0.0618
N/A N=101 PE PREMIER CHINA CLINICAL TRIAL
Atherosclerosis
Primary: Technical Success Rate — 99.1 percentage of participants
N/A N=368 Cingal Study for Knee Osteoarthritis
Knee Osteoarthritis
Primary: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score Comparing Cingal® to Saline (ITT) — -40.2; -36.1; -31.0 score on a scale — p=0.0099
N/A N=109 INGEVITY+ Active Fixation Pace/Sense Lead Clinical Study
Bradycardia
Primary: Primary Safety: Lead-related Complication-Free Rate — 98.5 Percentage of leads
N/A N=31 An Open Label Trial of TMS Therapy for Bipolar Depression
Bipolar Depression
Primary: The Percentage of Patients Who Respond or Remit After 30 to 35 Treatments Based Off of the Montgomery-Åsberg Depression Rating Scale (MADRS) — 27; 4; 23; 8 Participants…
Phase 1 N=24 Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
Age-Related Maculopathy · Age-Related Maculopathies · Eye Diseases
Primary: Number of Participants With Toxicity or Intolerable Dose Criteria — 0; 0; 0; 0 Participants
Phase 3 N=5 GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis
Bile Acid Synthesis Defect · Inborn Error of Bile Acid Metabolism · Inborn Error of Bile Acid Conjugation
Primary: Conjugated Cholic Acid (GCA) for the Treatment of Inborn Errors in Bile Acid Synthesis Involving Side-chain Conjugation. — 5 Participants
N/A N=20 Protection Against Insulin Resistance in Obesity
Obesity · Insulin Resistance
Primary: Insulin Sensitivity — 273; 817 nmol/kg FFM/min /(µU/mL Insulin)
Phase 2 N=275 Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
Renal Cell Carcinoma
Primary: Objective Response Rate (ORR) — 36.4; 26.7 Percentage of Participants
Phase 2 N=108 Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids
Asthma
Primary: Change From Baseline of Trough Forced Expiratory Volume in One Second (FEV1) Percent Predicted After 4 Weeks of Treatment — 0.128; 0.409; 0.798; 0.211 Percentage of…
Phase 2 N=164 A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Non-alcoholic Steatohepatitis
Primary: Percent Change From Baseline in Whole Liver Fat at Week 16 — -3.21; -16.12; -4.36 Percent change — p=0.0696
Phase 4 N=87 Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)
Multiple Sclerosis (MS)
Primary: The Time From Randomization to the First Demyelinating Event (Acute or Development of an Initial Symptom Resulting in a Progressive Clinical Course) — 89.69; 77.81 weeks
Phase 2 N=16 Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects
Diabetes Mellitus, Type 2
Primary: Number of Treatment Emergent Serious Adverse Events (TE-SAEs) — 0; 0; 0; 0 Treatment Emergent SAE